

1 **Patterns of Cervical and Masticatory Impairment in Subgroups of People**
2 **with Temporomandibular Disorders—an Explorative Approach Based on**
3 **Factor Analysis**
4

5 **Patterns of Cervical and Masticatory Impairment in Subgroups of People**
6 **with Temporomandibular Disorders—an Explorative Approach Based on**
7 **Factor Analysis**

8 **Abstract**

9 **Objectives**

10 To identify clinical patterns of impairment affecting the cervical spine and masticatory
11 systems in different subcategories of TMD by an explorative data driven approach.

12 **Methods**

13 For this observational study 144 subjects were subdivided according to Research
14 Diagnostic Criteria for Temporomandibular Disorders into: healthy controls,
15 temporomandibular joint (TMJ) signs without symptoms, TMJ affected,
16 temporomandibular muscles affected, or TMJ and muscles affected. Factor analysis was
17 applied to cervical spine and masticatory data while linear regression was applied to
18 characterize clinical patterns in subgroups.

19 **Results**

20 Factor analysis identified five clinical dimensions which explained 59% of all variance:
21 mechanosensitivity, cervical movement, cervical and masticatory dysfunction, jaw
22 movement, and upper cervical movement. Regression analysis identified different
23 clinical dimensions in each TMD subgroup.

24 **Conclusion**

25 Distinct clinical patterns of cervical spine and masticatory function were found among
26 subgroups of TMD, which has clinical implications for therapeutic management.

27 Factor analysis, subgroup, TMD, cervical, explorative

28 **Introduction**

29 Temporomandibular disorder (TMD) is an umbrella term for structural and functional
30 disorders related to the masticatory muscles and/or the temporomandibular joint
31 (TMJ) with or without clinical signs and symptoms (1). It is the second most common
32 cause of orofacial pain following dental pain (2). The prevalence of signs and
33 symptoms related to TMD ranges widely, reported as low as 1% and as high as 75%,
34 affecting more women and younger people which is uncommon for chronic pain
35 conditions (2–6). The inconsistent epidemiological data is assumed to be a result of
36 different unstandardized and heterogeneous diagnostic criteria used in the studies to
37 define TMD and its symptoms (2, 7). The major clinical signs and symptoms associated
38 with TMD are pain both local and referred into the temporal region of the head, lower
39 face and neck, as well as clicking sound's, reduced and painful mouth opening, and
40 bruxism (8–10). However, not all individuals diagnosed with TMD have symptoms (11)
41 and thus it is estimated that only 3% of people with signs of TMD seek medical aid
42 (10).

43 Biological as well as psychological aspects are assumed to be factors in the
44 development of TMD (12). As a consequence, according to Research Diagnostic
45 Criteria/TMD (RDC/TMD), classification of TMD will include physical or psychological
46 diagnoses. Under physical diagnosis, patients are classified into muscle disorders
47 and/or disc displacements and/or arthralgia, osteoarthritis or osteoarthrosis (1, 6, 13).
48 The importance of diagnosis is to identify the appropriate management strategy from
49 the broad spectrum of therapies described for this condition.

50 Within the contributing factors to TMD the cervical spine is considered to play a crucial
51 role (14). Studies show anatomical and pathophysiological interactions between the

52 cervical spine and TMJ region (15–21). For example, people with TMD show higher
53 prevalence and one-year-incidence for neck pain than those without TMD (20, 22).

54 Furthermore, it has been demonstrated that the neck disability index is highly
55 correlated with the jaw function scale (23). Studies have also demonstrated the
56 influence of various head and neck postures on the masticatory muscles and their
57 mechanosensitivity (18, 24). Additionally, there is some evidence that cervical
58 dysfunction is the consequence of TMD. As such, various authors describe a positive
59 effect of orofacial therapy (21, 25) on the function of the cervical spine. Yet, a clear
60 causal relationship remains unclear.

61 Despite this, there is little high quality research evidence that has investigated the
62 relationship between cervical dysfunction and TMD. Furthermore, according to the
63 author's knowledge, there are no studies investigating whether subgroups of TMD
64 show distinct patterns of cervical and masticatory impairment. Finally, studies are
65 lacking that give a comprehensive picture of the interaction between the cervical spine
66 and the TMJ.

67 Consequently, the aim of this study is to describe and perform an extensive analysis in
68 a study sample consisting of individuals classified into five subgroups according to
69 physical diagnostic criteria of RDC/TMD. Subgroups of TMD are characterized with
70 respect to patterns of impairment based on clinical and functional measurements
71 associated with the masticatory and cervical systems. Therefore, instead of testing
72 predefined, clinically driven hypotheses (which is the common way), this study uses an
73 explorative data driven approach based on factor analysis. More detailed knowledge of
74 clinical patterns of cervical and masticatory impairment among subgroups of TMD may
75 ultimately direct management and thereby improve therapeutic outcomes.

76 **Methods**

77 ***Participants***

78 For this observational study, subjects were recruited from physiotherapy practices in
79 Northern Germany by information flyers. Subjects were evaluated for inclusion by a
80 clinical expert with 15 years of experience managing orofacial pain according to the
81 following criteria: (1) age at least 18 years, (2) score of less than 3 on the modified
82 *Chronic Grade Pain Scale* (26–29) indicating chronic condition status , (3) conversant in
83 the German language, (4) score of more than 3 measured on the CONTI questionnaire
84 suggesting evidence of TMD (30).

85 Subjects acting as controls were selected from the same environment if they met the
86 following criteria: (1) age at least 18 years, (2) conversant in the German language, (3)
87 score of ≤ 3 measured by the CONTI questionnaire. Subjects were excluded if they had
88 (1) a history of surgery or fractures in the neck and jaw or (2) neurologic deficits or (3)
89 pain at night or other red flags or (4) were currently undergoing orthodontic
90 treatment. Prior to participation, subjects gave written informed consent. The study
91 was conducted in accordance with the Declaration of Helsinki and was approved by
92 the local ethics committee of the University of Applied Science Of Osnabrück.

93 For further stratification subjects were subdivided according to RDC/TMD. Therefore
94 the presence of painful and restricted mouth opening, painful masticatory muscles on
95 palpation, and TMJ sounds were assessed. These criteria are designed to define the
96 subgroup of TMD. (31). As a consequence, patients with TMD (CONTI > 3) were
97 subdivided into group “Arthogen” when joint disorders were present, group “Myogen”
98 when myofascial disorders were present, or into group “Mixed” when both joint
99 disorders and myofascial disorders were present. Subjects acting as controls (CONTI \leq

100 3) were subdivided into group “Controls” having no TMD signs or pain or group “Just
101 signs” having TMD signs that are not clinically relevant based on the Conti scale (30).
102 Consequently, five subgroups were investigated with different diagnoses of TMD. We
103 proposed that the “Mixed“ group would be the most severe as they had both joint
104 disorders and myofascial involvement.

105 ***Functional measurements***

106 The TMJ and the cervical spine were examined and measured separately by two
107 clinically experienced physiotherapists who had 8 hours intensive training in the
108 management of orofacial disorders. The investigator who executed the neck
109 measurements was blind to subjects TMD subgroup classification.

110 *TMJ Region*

111 *Range of motion*

112 Measurements of TMJ range of motion (ROM) included mouth opening, active lateral
113 shift of the jaw to both sides as well as active backward and forward movement of the
114 jaw. Inter- and Intra-rater reliability has been shown to be moderate to excellent for
115 these measurements.

116 *Mechanosensitivity*

117 Mechanosensitivity of the Masseter and Temporalis muscles was determined by
118 measuring pressure pain threshold (PPT) using an algometer (*Wagner instruments,*
119 *Force dial FDK 10*). Pressure was applied at a constant rate of approximately 1
120 kg/cm²/s until subjects reported the point when the sensation changed from pressure
121 to pain. Two readings were taken over each site and each muscle and averaged for
122 analysis. PPT has been shown to be a valid and reliable method for measuring
123 mechanosensitivity (32–34).

124 *CONTI*

125 The Conti questionnaire (30) was used for assessing TMD symptoms. This scale
126 comprises ten questions concerning typical TMD features and has a score from 0,
127 indicating no clinically relevant TMD, to 23. Prior to the examination subjects were
128 asked whether they suffered from pain in the masticatory and cervical region.

129 *PAIN*

130 Pain was graded according to the Colored Analogue Scale (CAS) from 0 to 10. The CAS
131 has high reproducibility (35).

132 *Cervical spine*

133 *ROM*

134 Active cervical ROM in all planes (flexion, extension, lateral flexion, and rotation) was
135 measured by the Cervical ROM (CROM) device (36, 37). Maximum angles within
136 comfortable limits were recorded. The CROM device is described as valid and reliable
137 (36, 38, 39).

138 *Mechanosensitivity*

139 Mechanosensitivity of Upper Trapezius and Obliquus Capitis Inferior muscles were
140 determined by measuring PPT using the method described above.

141 *Neck disability index*

142 The Neck disability index (NDI) was used to assess neck related disability and
143 comprises 10 self-report questions covering activities of daily living, concentration and
144 pain. The scale ranges from 0 (no pain and disability) to 50 (severe pain and disability)
145 and has been shown to have good to excellent psychometric properties (40, 41).

146 *Flexion-Rotation Test*

147 Upper cervical rotation in end-range flexion (FRT) (42, 43) was recorded using a digital
148 goniometer (Halo Medical Device), while pain during the FRT was recorded by the CAS.

149 *Cranio-cervical Flexion-Test*

150 The Cranio-cervical Flexion-Test (CCFT) was used to measure endurance of the cervical
151 deep flexor muscles (44, 45) evaluated using a pressure biofeedback device
152 (*Chattanooga, USA*) according to a reliable procedure described by Hudswell (46–48).

153 *Number of cervical signs*

154 Palpation of the three upper cervical spine motion segments was conducted to assess
155 segmental mobility and pain. The number of symptomatic findings were aggregated
156 and termed “cervical signs”. This procedure has good reliability (49).

157 All measurements are summarized in Table S1 available online.

158 ***Analysis***

159 All statistical analysis was performed with R (50) including the psych package (51).

160 Analysis of variance and χ^2 was used to test for differences in baseline characteristics
161 between subgroups of participants. P-values < 0.05 were considered significant. The
162 basis of our analysis strategy was as follows: Rather than confirming whether clinically
163 driven predefined clinical patterns are present among subjects with TMD, we
164 performed a data driven explorative analysis strategy in order to identify clinically
165 relevant patterns among subgroups of individuals with TMD. Therefore we conducted
166 five steps including factor analysis and linear regression analysis.

167 Step 1: Factor analysis was used as a dimension reduction method. Measured variables
168 were condensed to a reduced number of factors that would still contain the majority
169 of the information from the original data. The dimensionality of the data was assessed,
170 where each factor represents a clinical dimension which was characterized with

171 respect to a clinical meaning. The appropriate number of relevant clinical dimensions
172 was established by applying the Very Structure Criterion (52) and the Parallel Analysis
173 Criterion (53) as implemented in the psychological package. Where inconsistency of
174 the statistical solutions was detected the more interpretable solution with respect to
175 clinical meaning was selected. The amount of information (variance) that is captured
176 by each of extracted factors was calculated by determining their eigenvalues.

177 Step 2: graphical descriptive means were used to assess the ability of the data to
178 discriminate people with TMD from controls in general. A scatterplot representing
179 each individual's score for each pair of factors was constructed demonstrating the
180 general clinical relevance of the identified dimensions.

181 Step 3: the extracted factors (clinical dimensions), were interpreted with respect to a
182 clinical and functional meaning. Therefore, all measured variables were correlated
183 with the extracted factors. Their correlation coefficients represent their loadings on
184 the factors. By inspecting the correlation coefficients of each measured variable with
185 each factor the contribution of each variable to the respective factor was evaluated. As
186 a consequence, the clinical meaning of the factors was interpreted. In order to
187 facilitate interpretation, the factor solution was rotated before calculating the
188 correlation structure, in our case by Varimax rotation. Conceptually, the factors have
189 the function of summary variables of the underlying clinical dimension. The score of
190 each individual on each factor was calculated. As a consequence, it was possible to
191 quantify each person's score on the respective clinical dimension, i.e. a low/high
192 person's score represents a low/high summary score of the respective clinical
193 dimension.

194 Step 4: subgroup characterization was performed with respect to the clinical
195 dimensions. Therefore, we aimed to determine to what extent each of the TMD
196 subgroups was affected with respect to the respective clinical dimension. To do so we
197 conducted the analysis with both the extracted factors, representing the clinical
198 dimensions as summary variables, and with the original variables contributing to the
199 respective clinical dimensions. For this purpose we used linear regression with
200 subgroup membership as independent variables and all variables standardized
201 (Mean=0, SD=1). Results are given as standardized mean differences and interpreted
202 as effect sizes according to Cohen (<0.2 no effect, 0.2-0.5 small effect, 0.5-0.8
203 moderate, 0.8>large effect) (56). This approach is analogous to meta- analysis in order
204 to be able to compare results across outcomes with different units.

205 Step 5: Finally, a summary was generated of how the TMD subgroups were
206 characterized with respect to the identified clinical dimensions. Also, here the strength
207 of clinical impairment in each dimension was given as interpretable values according to
208 Cohen. Hence, the clinical pattern of each subgroup was presented indicating which
209 clinical dimension was affected to which extent.

210 The quality of the factor analysis models was assessed using Bartlett's test for
211 sphericity (54) and the Kaiser-Meyer-Olkin test (55). For regression analysis, variables
212 that assessed bilateral measurements were combined to one variable by calculating
213 the mean of left and right sides as no significant side differences were present.

214 Additionally, we added age and gender as covariates into regression models as
215 potential confounders. If p-values of confounders according to t-statistics were >0.1, or
216 changed the estimate less than 10%, those variables were withdrawn from the model.

217 **Results**

218 Of 175 people assessed for inclusion 144 participants met the study criteria. These
219 people were divided into five subgroups and characterized with respect to clinical
220 patterns of impairment based on clinical and functional measurements from the TMJ
221 and cervical spine as depicted in the work flow diagram in Figure 1.

222 Figure 1:

223 Baseline characteristics are summarized in Table 1.

224 Bartlett's Test of Sphericity was highly significant (Chi square = 1513.003, $P < 0.001$)
225 and the KMO test was 0.82, supporting the suitability of the data for factor analysis.

226 Step 1 clinical dimensionality of data: We extracted 5 independent factors by factor
227 analysis representing five clinical dimensions. In total, the five dimensions explained
228 59% of the total variance (dimension 1 - 23%, dimension 2 - 13%, dimension 3 - 8%,
229 dimension 4 - 8%, and dimension 5 - 5%).

230 Step 2 general overview of distinction between subjects with TMD and controls: Figure
231 2 shows the scores of all individuals on each of the five factors, i.e. on each clinical
232 dimension. Each scatter plot shows each individual's score of a pair of dimensions. E.g.
233 the very left top plot depicts scores of dimension 1 on the x-axis and scores of
234 dimension 2 on the y-axis. Black Cs represent the control group including the control
235 group with symptoms of TMD. Grey Ts represent the TMD group including sub-groups
236 "Arthrogn", "Myogen" and "Mixed". Plots of dimension 1 to dimension 4 show, albeit
237 some overlap of the dots, that the scores of subjects with TMD are separate to the
238 scores of controls indicating that subjects with TMD generally possess distinct
239 underlying clinical patterns compared to controls. This especially holds true for the
240 third dimension. Factor 5 suggests no distinct pattern between the groups.

241 Figure 2:

242 Step 3 Characterization of clinical dimensions. In Table 2 the factor loadings of each
243 measured variable are listed. The key variables of each independent factor, i.e. clinical
244 dimension, are marked in grey. The values are the correlation coefficients of each
245 measured variable with each factor. This allows the clinical and functional
246 interpretation of the clinical dimensions. As a consequence, factor 1 represents the
247 clinical dimension “mechanosensitivity” as it includes all variables measuring
248 mechanosensitivity of muscle sites in the masticatory and cervical region as well as the
249 variable “cervical signs” (coefficient range: 0.64-0.89). Factor 2 is characterized by the
250 clinical dimension cervical ROM which includes movement in all directions (coefficient
251 range: 0.54-0.81). Factor 3 comprises both cervical and masticatory dysfunction
252 measured by the NDI and CONTI questionnaires, as well as the presence of pain when
253 performing the FRT (coefficient range: 0.47-0.72). As a consequence we called this
254 clinical dimension “Cervical/masticatory dysfunction and pain”. Factor 4 represents the
255 clinical dimension “jaw movements” which includes TMJ movement in all directions
256 (coefficient range: 0.43-0.7). The last factor consists of the clinical dimension FRT ROM
257 and the CCFT (coefficient range: 0.45-0.78).

258 Table 2:

259 Step 4 Characterization of TMD subgroups: Figure 3 shows the pairwise differences
260 between each of the subgroups compared to the Control group with respect to all
261 clinical dimensions including all contributing variables. Linear regression was used for
262 this analysis. The first variable of each column and each pairwise comparison
263 (summary variable) represents the extracted factors by factor analysis and is
264 considered as the summary variable of each corresponding clinical dimension for the
265 respective group comparison. Below each summary variable the contributing variables

266 to each clinical dimension, according to Table 2, are listed. The effects of the
267 subgroups “Mixed”, “Myogen”, “Arthrogen” and “Just signs” in comparison to the
268 reference group (control group without TMD signs) are presented as standardized
269 mean differences (SMD) and $\pm 95\%$ Confidence Intervals. It allows interpretation of the
270 coefficients in effect size. In the dimension “mechanosensitivity” the overall effect size
271 represented by its summary variable for the comparison “Mixed” group vs control
272 group is -0.83 [-1.32;-0.38] suggesting a large effect. In others words this means that in
273 general, mechanosensitivity of the “Mixed” group is greatly elevated when compared
274 to “Controls”. This effect is consistent across all single variables of the clinical
275 dimension “mechanosensitivity”. The variables range from -0.77 for Temporalis muscle
276 to 0.92 for “cervical signs”. The second largest effect size with respect to the clinical
277 dimension “mechanosensitivity” is observed between the “Myogen” group and the
278 control group with an effect size of -0.39 [-0.96;0.21]. In the remaining two groups the
279 effect size is below -0.25. For the dimension “cervical mobility” a similar pattern is
280 observed. Also here the “Mixed” group has the most reduced cervical ROM with an
281 effect size of -0.58 [-1.06;-0.10] followed by the “Myogen” group having an effect size
282 of -0.38 [-0.99;0.23]. The most affected direction in both the “Mixed” and “Myogen”
283 group is extension with effect sizes of -0.69 [-1.16;-0.23] and -0.63 [-1.19;-0.06]
284 respectively. The least affected variable in both groups is flexion (effect size in the
285 “Mixed” group: -0.27[-0.78;0.24], effect size in the “Myogen” group: -0.36 [-
286 0.98;0.26]).

287 Dimension “Cervical/masticatory dysfunction and pain”, is similarly impaired in all
288 subgroups apart from “Just signs” group. The large effect sizes of the summary
289 variables range from -0.94[-0.50;-1.38] in the “Mixed” group to -1.28 [-0.72;-1.83] in

290 the “Myogen” group. The effect sizes for the single variables CONTI, NDI and pain
291 during FRT range in the three affected subgroups between -0.78 [-0.33;1.20] and -1.69
292 [-1.35;-2.04]. Acute pain is only present in the “Myogen” group with an moderate
293 effect size of -0.71 [-0.27;-1.15]. Dimension 4 “jaw movement” is restricted across all
294 subgroups with moderate effects sizes of the summary variables from -0.54 [-
295 1.15;0.08] in the “Myogen” group to -0.77[-1.27;-0.26] in the “Mixed” group. Finally,
296 the last dimension has no clinical meaning for any of the subgroups indicated by effect
297 sizes lower than 0.20.

298 Figure 3:

299 Step 5 summary of clinical patterns in TMD subgroups:

300 In Table 3 the clinical patterns with respect to the cervical and masticatory systems of
301 the subgroups are depicted. Arrows indicate to which extent a subgroup is restricted in
302 each clinical dimension and represent effect sizes stemming from the summary
303 variables of each clinical dimension shown in figure 3. One arrow is a small effect, two
304 arrows a medium effect and three arrows a large effect. As a consequence, the
305 “Mixed” group is the most affected group, with moderate to large limitations in the
306 dimensions “mechanosensitivity”, “cervical ROM”, “cervical and masticatory
307 dysfunction and pain” and “jaw movement”. The “Myogen” group is also affected in
308 the same dimensions, however, less with respect to “mechanosensitivity” and “cervical
309 ROM”. Groups “Arthrogen” and “Just signs” have only medium to large limitations in
310 dimensions “cervical and masticatory dysfunction and pain” and jaw movement.

311 Table 3:

312 **Discussion**

313 In this explorative data driven analysis five independent clinical dimensions were
314 identified based on 28 functional measurements from the cervical spine and
315 masticatory systems using factor analysis with varimax rotation and linear regression
316 analysis. These dimensions are interpreted as mechanosensitivity, cervical ROM,
317 cervical and masticatory dysfunction, jaw movement and upper cervical
318 ROM/endurance. The five factors explain 59% of all variance. Furthermore, the 144
319 subjects divided into five subgroups according to RDC/TMD were characterized with
320 respect to the five clinical dimensions. The “Mixed“ group is the most affected group
321 with moderate to large limitations in all dimensions followed by the “Myogen“ group
322 with limitations in the same dimensions, however, less with respect to
323 mechanosensitivity and cervical ROM. Groups “Arthrogen“ and “Just signs“ show
324 medium to large limitations only concerning cervical and masticatory dysfunction and
325 jaw movement. A clear dose response relationship was observed indicating that
326 subjects with a diagnosis of TMD in two aspects (myogenic and arthrogenic) are most
327 affected.

328 The main advantage of this explorative data driven approach is that it revealed clinical
329 patterns that were quite unexpected and probably would have not been identified by
330 a clinically driven approach. This is illustrated by two findings as examples: Firstly, the
331 clinical dimension “mechanosensitivity“ consisted of variables measuring
332 mechanosensitivity at all muscle sites, not just over cervical or masticatory muscles.
333 From the clinical point of view one might have expected two distinct dimensions,
334 namely “cervical mechanosensitivity“ and “masticatory mechanosensitivity“. However,
335 due to the high correlation structure the analysis revealed that the two regions are
336 highly interrelated with respect to mechanosensitivity and may not be seen as

337 clinically different problems. On the one hand this finding confirms the fact that
338 subjects with TMD suffer from referred pain into the neck region. On the other hand,
339 this finding perhaps suggests that patients with TMD are dominated by mechanism(s)
340 of central sensitization with associated areas of secondary hyperalgesia.

341 A similar surprising result was seen for the variables NDI and CONTI which were found
342 to occur together in one dimension. Even though it is known (25, 57–59) that these
343 two variables are correlated, it was surprising that both variables were related so
344 much to each other that they loaded equally highly on the same factor. From the
345 clinical point of view one might have expected that the variable NDI would cluster
346 together with variables measuring neck muscle mechanosensitivity or cervical ROM.

347 Additionally, the CONTI might be expected to cluster together with jaw movements or
348 variables measuring masticatory muscle mechanosensitivity .

349 In this study, ROM of the upper cervical spine together with endurance of the neck
350 flexors were not found to have any clinical relevance for any subgroup. (60) This is in
351 contrast to previous studies showing evidence of altered upper cervical spine ROM and
352 muscle performance in TMD overall and in specific sub-groups of people with TMD (16,
353 59–61). The difference could be explained by the small sample size in some studies
354 (60, 61), but that was not the case in the study by Armijo-Olivo and Magee (59).

355 Further studies are required to elucidate this.

356 Less surprising is that fact that the “Mixed” group was the most affected group. One
357 might expect this finding from the clinical point of view as well.

358 A further advantage of the present study is the use of the extracted factors as
359 summary variables of each identified clinical dimension. In that way a summary score
360 of each clinical dimension could be calculated for each individual. As a consequence

361 high/low individual scores mean large/low limitations in the respective dimension. The
362 clinical relevance of this information requires careful consideration. These results
363 confirm that patient's with TMD are not homogenous, different subgroups exist with
364 different clinical presentations. Each subgroup may therefore require a different form
365 of intervention to address the underlying mechanisms.

366 Clinical Implications

367 The findings of this study have clinical implications for practice. In general there is a
368 need to subgroup patients with TMD as they have distinct functional profiles with
369 respect to the cervical and masticatory systems. Typically, this kind of procedure is
370 conducted in daily clinical practice by therapists where individuals are categorized
371 based on a comprehensive clinical evaluation in order to initialize individually tailored
372 therapy and patient management programs (63). Similar broad-based evaluative
373 approaches are undertaken in patients with low back pain (64). Furthermore it has
374 been shown that sub-classification based therapy is more effective than standard
375 protocols (65–68).

376 The fact that NDI and CONTI are highly interrelated to form one clinical dimension
377 suggests that when patients present with high levels of impairment of TMD, high levels
378 of disability of the cervical region should also be expected. This holds true across all
379 subgroups of TMD. As a consequence, management should address impaired domains
380 detected by the NDI and CONTI.

381 It would appear reasonable to suggest that for patients with arthrogenic and myogenic
382 features of TMD, management should address mechanosensitivity of masticatory and
383 neck muscles. However, the underlying pain mechanism in this dimension are
384 indicative of central sensitization which requires a different management approach.

385 Impaired mechanosensitivity seems to be less likely among patients with myogenic
386 TMD and almost nonexistent in patients with arthrogenic TMD.

387 Cervical ROM is another clinical dimension that seems to be problematic and needs
388 attention in clinical practice in patients with „Mixed“ TMD, but less so in myogenic
389 and arthrogenic TMD. In contrast, restricted ROM of the TMJ is similarly present
390 across all TMD subgroups.

391 In general, it can be noted that in none of the clinical dimensions does a single variable
392 stand out that requires specific attention. For example, in the clinical dimension
393 mechanosensitivity, there is not a single muscle alone that is affected. All muscles are
394 equally affected. The same holds true for cervical ROM, where it is not a single
395 movement but all planes that are equally affected.

396 Strengths

397 The strength of this paper is the application of factor analysis as an explorative data
398 driven approach to characterize predefined subgroups with respect to until now
399 unknown clinical patterns. This approach is unusual and not commonly applied.
400 However, it has yielded unexpected but clinically meaningful and relevant implications.
401 This was only possible due to a large sample size and detailed and extensive
402 measurements which is uncommon in studies of TMD.

403 However, there are other statistical approaches that perform subgroup classification
404 based on data modelling. Common statistical techniques include among others cluster
405 or latent class analysis. Instead of predefining subgroups based on clinical diagnosis
406 these techniques create subgroups based on the observed data. Consequently, built
407 classes are interpreted and analyzed with respect to clinical relevance (69).

408 Limitations

409 A potential weakness of this study is the exclusion of patients with chronic disease. As
410 a result, it is not possible to draw any conclusions regarding those patients.
411 Furthermore, this study did not include psychosocial aspects in the factor analysis. In
412 addition, in an attempt to control for potential confounders it was not possible to use
413 a matched case controlled design. Matched case controlled designs allow more
414 efficient statistical analysis approaches resulting in more power. Finally, in order to
415 disentangle the temporal relationship between onset of cervical spine and masticatory
416 complaints, a longitudinal study designs is necessary.
417 For the purpose of validation it is essential to replicate the study findings in further
418 research. The presence of the identified clinical dimensions and patterns among
419 subgroups of TMD need to be confirmed by confirmatory factor analysis in other
420 samples.

421 Conclusion

422 An explorative data driven analysis was used for identifying clinical patterns among
423 subgroups of TMD. These results have implications for clinical decision making and
424 therapeutic management in patients with TMD. As a consequence, it is proposed that
425 subgrouping patients with TMD is essential as these show distinctly different clinical
426 patterns with respect to the masticatory and cervical spine systems in order to improve
427 outcomes.

428

429 **References**

- 430 1. Dworkin SF, Huggins KH, LeResche L, Korff M v., Howard J, Truelove E, Sommers E.
431 Epidemiology of signs and symptoms in temporomandibular disorders: clinical signs in
432 cases and controls. J Am Dent Assoc 1990;120(3):273. eng.

- 433 2. Manfredini D, Guarda-Nardini L, Winocur E, Piccotti F, Ahlberg J, Lobbezoo F. Research
434 diagnostic criteria for temporomandibular disorders: a systematic review of axis I
435 epidemiologic findings. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*
436 2011;112(4):453. eng. doi:10.1016/j.tripleo.2011.04.021.
- 437 3. Johansson A, Unell L, Carlsson GE, Soderfeldt B, Halling A. Gender difference in
438 symptoms related to temporomandibular disorders in a population of 50-year-old
439 subjects. *J Orofac Pain* 2003;17(1):29. eng.
- 440 4. Macfarlane TV, Blinkhorn AS, Davies RM, Kincey J, Worthington HV. Oro-facial pain in
441 the community: prevalence and associated impact. *Community Dent Oral Epidemiol*
442 2002;30(1):52. eng.
- 443 5. Shaffer SM, Brismee J-M, Sizer PS, Courtney CA. Temporomandibular disorders. Part 1:
444 anatomy and examination/diagnosis. *J Man Manip Ther* 2014;22(1):2. eng.
445 doi:10.1179/2042618613Y.0000000060.
- 446 6. LeResche L. Epidemiology of temporomandibular disorders: implications for the
447 investigation of etiologic factors. *Crit Rev Oral Biol Med* 1997;8(3):291. eng.
- 448 7. Poveda Roda R, Bagan JV, Diaz Fernandez, Jose Maria, Hernandez Bazan S, Jimenez
449 Soriano Y. Review of temporomandibular joint pathology. Part I: classification,
450 epidemiology and risk factors. *Med Oral Patol Oral Cir Bucal* 2007;12(4):E292-8. eng.
- 451 8. Svensson P, Graven-Nielsen T. Craniofacial muscle pain: review of mechanisms and
452 clinical manifestations. *J Orofac Pain* 2001;15(2):117. eng.
- 453 9. Thilander B, Lennartsson B. A study of children with unilateral posterior crossbite,
454 treated and untreated, in the deciduous dentition--occlusal and skeletal characteristics
455 of significance in predicting the long-term outcome. *J Orofac Orthop* 2002;63(5):371.
456 eng;ger. doi:10.1007/s00056-002-0210-6.
- 457 10. De Kanter, R J, Truin GJ, Burgersdijk RC, Van 't Hof, M A, Battistuzzi PG, Kalsbeek H,
458 Kayser AF. Prevalence in the Dutch adult population and a meta-analysis of signs and
459 symptoms of temporomandibular disorder. *J Dent Res* 1993;72(11):1509. eng.
- 460 11. Gesch D, Bernhardt O, Kocher T, John U, Hensel E, Alte D. Association of malocclusion
461 and functional occlusion with signs of temporomandibular disorders in adults: results of
462 the population-based study of health in Pomerania. *Angle Orthod* 2004;74(4):512. eng.
463 doi:10.1043/0003-3219(2004)074<0512:AOMAFO>2.0.CO;2.
- 464 12. Armijo Olivo S, Magee DJ, Parfitt M, Major P, Thie, Norman M R. The association
465 between the cervical spine, the stomatognathic system, and craniofacial pain: a critical
466 review. *J Orofac Pain* 2006;20(4):271. eng.
- 467 13. Leeuw de R, Klasser GD. Orofacial pain. Guidelines for assessment, diagnosis, and
468 management. Chicago: Quintessence Publishing Co, 2013.
- 469 14. Bogduk N. Cervicogenic headache: anatomic basis and pathophysiologic mechanisms.
470 *Curr Pain Headache Rep* 2001;5(4):382. eng.
- 471 15. Rocabado M. Biomechanical relationship of the cranial, cervical, and hyoid regions. *J*
472 *Craniofacial Pract* 1983;1(3):61. eng.
- 473 16. Laats A de, Meuleman H, Stevens A, Verbeke G. Correlation between cervical spine and
474 temporomandibular disorders. *Clin Oral Investig* 1998;2(2):54. eng.

- 475 17. Xiong G, Matsushita M. Upper cervical afferents to the motor trigeminal nucleus and the
476 subnucleus oralis of the spinal trigeminal nucleus in the rat: an anterograde and
477 retrograde tracing study. *Neurosci Lett* 2000;286(2):127. eng.
- 478 18. Ballenberger N, Piekartz H v., Paris-Aleman A, La Touche R, Angulo-Diaz-Parreno S.
479 Influence of different upper cervical positions on electromyography activity of the
480 masticatory muscles. *J Manipulative Physiol Ther* 2012;35(4):308. eng.
481 doi:10.1016/j.jmpt.2012.04.020.
- 482 19. Armijo-Olivo S, Silvestre RA, Fuentes JP, da Costa, Bruno R, Major PW, Warren S, Thie,
483 Norman M R, Magee DJ. Patients with temporomandibular disorders have increased
484 fatigability of the cervical extensor muscles. *Clin J Pain* 2012;28(1):55. eng.
485 doi:10.1097/AJP.0b013e31822019f2.
- 486 20. Visscher CM, Lobbezoo F, Boer W de, van der Zaag, J, Naeije M. Prevalence of cervical
487 spinal pain in craniomandibular pain patients. *Eur J Oral Sci* 2001;109(2):76. eng.
- 488 21. Piekartz H v., Hall T. Orofacial manual therapy improves cervical movement impairment
489 associated with headache and features of temporomandibular dysfunction: a
490 randomized controlled trial. *Man Ther* 2013;18(4):345. eng.
491 doi:10.1016/j.math.2012.12.005.
- 492 22. Hoy DG, Protani M, De R, Buchbinder R. The epidemiology of neck pain. *Best Pract Res*
493 *Clin Rheumatol* 2010;24(6):783. eng. doi:10.1016/j.berh.2011.01.019.
- 494 23. Olivo SA, Fuentes J, Major PW, Warren S, Thie, N M R, Magee DJ. The association
495 between neck disability and jaw disability. *J Oral Rehabil* 2010;37(9):670. eng.
496 doi:10.1111/j.1365-2842.2010.02098.x.
- 497 24. La Touche R, París-Aleman A, Piekartz H v., Mannheimer JS, Fernández-Carnero J,
498 Rocabado M. The influence of cranio-cervical posture on maximal mouth opening and
499 pressure pain threshold in patients with myofascial temporomandibular pain disorders.
500 *Clin J Pain* 2011;27(1):48. eng. doi:10.1097/AJP.0b013e3181edc157.
- 501 25. Piekartz H v., Ludtke K. Effect of treatment of temporomandibular disorders (TMD) in
502 patients with cervicogenic headache: a single-blind, randomized controlled study. *Cranio*
503 2011;29(1):43. eng. doi:10.1179/crn.2011.008.
- 504 26. Türp JC, Marinello CP. Schmerzfragebogen für Patienten mit chronischen orofazialen
505 Schmerzen. *Die Quintessenz* 2002;2002(12):
- 506 27. Smith BH, Penny KI, Purves AM, Munro C, Wilson B, Grimshaw J, Chambers WA, Smith
507 WC. The Chronic Pain Grade questionnaire: validation and reliability in postal research.
508 *Pain* 1997;71(2):141. eng.
- 509 28. Elliott AM, Smith BH, Smith WC, Chambers WA. Changes in chronic pain severity over
510 time: the Chronic Pain Grade as a valid measure. *Pain* 2000;88(3):303. eng.
- 511 29. John MT, Hirsch C, Reiber T, Dworkin SF. Translating the research diagnostic criteria for
512 temporomandibular disorders into German: evaluation of content and process. *J Orofac*
513 *Pain* 2006;20(1):43. eng.
- 514 30. Conti PC, Ferreira PM, Pegoraro LF, Conti JV, Salvador MC. A cross-sectional study of
515 prevalence and etiology of signs and symptoms of temporomandibular disorders in high
516 school and university students. *J Orofac Pain* 1996;10(3):254. eng.

- 517 31. Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet J-P, List T, Svensson P,
518 Gonzalez Y, Lobbezoo F, Michelotti A, Brooks SL, Ceusters W, Drangsholt M, Ettlin D,
519 Gaul C, Goldberg LJ, Haythornthwaite JA, Hollender L, Jensen R, John MT, Laat A de,
520 Leeuw R de, Maixner W, van der Meulen, Marylee, Murray GM, Nixdorf DR, Palla S,
521 Petersson A, Pionchon P, Smith B, Visscher CM, Zakrzewska J, Dworkin SF. Diagnostic
522 Criteria for Temporomandibular Disorders (DC/TMD) for Clinical and Research
523 Applications: recommendations of the International RDC/TMD Consortium Network*
524 and Orofacial Pain Special Interest Groupdagger. *J Oral Facial Pain Headache*
525 2014;28(1):6. eng. doi:10.11607/jop.1151.
- 526 32. Nussbaum EL, Downes L. Reliability of clinical pressure-pain algometric measurements
527 obtained on consecutive days. *Phys Ther* 1998;78(2):160. eng.
- 528 33. Grossi DB, Chaves TC, Goncalves MC, Moreira VC, Canonica AC, Florencio LL, Bordini CA,
529 Speciali JG, Bigal ME. Pressure pain threshold in the craniocervical muscles of women
530 with episodic and chronic migraine: a controlled study. *Arq Neuropsiquiatr*
531 2011;69(4):607. eng.
- 532 34. Persson AL, Brogardh C, Sjolund BH. Tender or not tender: test-retest repeatability of
533 pressure pain thresholds in the trapezius and deltoid muscles of healthy women. *J*
534 *Rehabil Med* 2004;36(1):17. eng.
- 535 35. Bulloch B, Garcia-Filion P, Notricia D, Bryson M, McConahay T. Reliability of the color
536 analog scale: repeatability of scores in traumatic and nontraumatic injuries. *Acad Emerg*
537 *Med* 2009;16(5):465. eng. doi:10.1111/j.1553-2712.2009.00404.x.
- 538 36. Youdas JW, Carey JR, Garrett TR. Reliability of measurements of cervical spine range of
539 motion--comparison of three methods. *Phys Ther* 1991;71(2):98-104; discussion 105-6.
540 eng.
- 541 37. Zito G, Jull G, Story I. Clinical tests of musculoskeletal dysfunction in the diagnosis of
542 cervicogenic headache. *Man Ther* 2006;11(2):118. eng. doi:10.1016/j.math.2005.04.007.
- 543 38. Audette I, Dumas J-P, Côté JN, De Serres, Sophie J. Validity and between-day reliability
544 of the cervical range of motion (CROM) device. *J Orthop Sports Phys Ther*
545 2010;40(5):318. eng. doi:10.2519/jospt.2010.3180.
- 546 39. Tousignant M, Duclos E, Lafleche S, Mayer A, Tousignant-Laflamme Y, Brosseau L,
547 O'Sullivan JP. Validity study for the cervical range of motion device used for lateral
548 flexion in patients with neck pain. *Spine (Phila Pa 1976)* 2002;27(8):812. eng.
- 549 40. Vernon H. The Neck Disability Index: state-of-the-art, 1991-2008. *J Manipulative Physiol*
550 *Ther* 2008;31(7):491. eng. doi:10.1016/j.jmpt.2008.08.006.
- 551 41. Cramer H, Lauche R, Langhorst J, Dobos GJ, Michalsen A. Validation of the German
552 version of the Neck Disability Index (NDI). *BMC Musculoskelet Disord* 2014;1591. eng.
553 doi:10.1186/1471-2474-15-91.
- 554 42. Takasaki H, Hall T, Oshiro S, Kaneko S, Ikemoto Y, Jull G. Normal kinematics of the upper
555 cervical spine during the Flexion-Rotation Test - In vivo measurements using magnetic
556 resonance imaging. *Man Ther* 2011;16(2):167. eng. doi:10.1016/j.math.2010.10.002.
- 557 43. Hall T, Robinson K. The flexion-rotation test and active cervical mobility--a comparative
558 measurement study in cervicogenic headache. *Man Ther* 2004;9(4):197. eng.
559 doi:10.1016/j.math.2004.04.004.

- 560 44. Cagnie B, D'Hooge R, Achten E, Cambier D, Danneels L. A magnetic resonance imaging
561 investigation into the function of the deep cervical flexors during the performance of
562 craniocervical flexion. *J Manipulative Physiol Ther* 2010;33(4):286. eng.
563 doi:10.1016/j.jmpt.2010.03.010.
- 564 45. Falla DL, Jull GA, Hodges PW. Patients with neck pain demonstrate reduced
565 electromyographic activity of the deep cervical flexor muscles during performance of
566 the craniocervical flexion test. *Spine (Phila Pa 1976)* 2004;29(19):2108. eng.
- 567 46. Hudswell S, Mengersen M v., Lucas N. The cranio-cervical flexion test using pressure
568 biofeedback: A useful measure of cervical dysfunction in the clinical setting?
569 *International Journal of Osteopathic Medicine* 2005;8(3):98.
570 doi:10.1016/j.ijosm.2005.07.003.
- 571 47. Jull G, Barrett C, Magee R, Ho P. Further clinical clarification of the muscle dysfunction in
572 cervical headache. *Cephalalgia* 1999;19(3):179. eng.
- 573 48. James G, Doe T. The craniocervical flexion test: intra-tester reliability in asymptomatic
574 subjects. *Physiother Res Int* 2010;15(3):144. eng. doi:10.1002/pri.456.
- 575 49. Hall T, Briffa K, Hopper D. The influence of lower cervical joint pain on range of motion
576 and interpretation of the flexion-rotation test. *J Man Manip Ther* 2010;18(3):126. eng.
577 doi:10.1179/106698110X12640740712293.
- 578 50. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria:
579 R Foundation for Statistical Computing; 2014. Available from: [http://www.R-](http://www.R-project.org/)
580 [project.org/](http://www.R-project.org/).
- 581 51. William Revelle. *psych: Procedures for Psychological, Psychometric, and Personality*
582 *Research*. Evanston, Illinois; 2014. Available from: [http://CRAN.R-](http://CRAN.R-project.org/package=psych)
583 [project.org/package=psych](http://CRAN.R-project.org/package=psych).
- 584 52. Revelle W, Rocklin T. Very simple structure: An alternative procedure for estimating the
585 optimal number of interpretable factors. *Multivariate Behavioral Research*
586 1979;14(4):403.
- 587 53. Humphreys LG, Montanelli Jr., Richard G. An Investigation of the Parallel Analysis
588 Criterion for Determining the Number of Common Factors. *Multivariate Behavioral*
589 *Research* 2010;10(2):193. doi:10.1207/s15327906mbr1002_5.
- 590 54. Cohen J. A power primer. *Psychological bulletin* 1992;112(1):155.
- 591 55. Bartlett MS. The Effect of Standardization on a chi square Approximation in Factor
592 Analysis. *Biometrika* 1951;1951(38):337.
- 593 56. Kaiser H. Analysis of factorial simplicity. *psychometrika* 1974;1974(39):31.
- 594 57. Silveira A, Gadotti IC, Armijo-Olivo S, Biasotto-Gonzalez DA, Magee D. Jaw Dysfunction Is
595 Associated with Neck Disability and Muscle Tenderness in Subjects with and without
596 Chronic Temporomandibular Disorders. *Biomed Res Int* 2015;2015512792. eng.
597 doi:10.1155/2015/512792.
- 598 58. da Costa, Dayse Regina Alves, de Lima Ferreira, Ana Paula, Pereira, Thaís Alves Barreto,
599 Porporatti AL, Conti, Paulo César Rodrigues, Costa YM, Bonjardim LR. Neck disability is
600 associated with masticatory myofascial pain and regional muscle sensitivity. *Arch. Oral*
601 *Biol.* 2015;60(5):745. eng. doi:10.1016/j.archoralbio.2015.02.009.

- 602 59. Armijo-Olivo S, Magee D. Cervical musculoskeletal impairments and temporomandibular
603 disorders. *J Oral Maxillofac Res* 2013;3(4):e4. eng. doi:10.5037/jomr.2012.3404.
- 604 60. Grondin F, Hall T, Laurentjoye M, Ella B. Upper cervical range of motion is impaired in
605 patients with temporomandibular disorders. *Cranio* 2015;33(2):91. eng.
606 doi:10.1179/0886963414Z.00000000053.
- 607 61. Bevilaqua-Grossi D, Chaves TC, de Oliveira, Anamaria Siriani. Cervical spine signs and
608 symptoms: perpetuating rather than predisposing factors for temporomandibular
609 disorders in women. *J Appl Oral Sci* 2007;15(4):259. eng.
- 610 62. Weber P, Correa, Eliane Castilhos Rodrigues, Ferreira, Fabiana dos Santos, Soares JC,
611 Bolzan, Geovana de Paula, Silva, Ana Maria Toniolo da. Cervical spine dysfunction signs
612 and symptoms in individuals with temporomandibular disorder. *J Soc Bras Fonoaudiol*
613 2012;24(2):134. eng;por.
- 614 63. Piekartz H v. Kiefer, Gesichts- und Zervikalregion, Neuromuskuloskeletale Untersuchung,
615 Therapie und Management. 2nd ed. Stuttgart: Thieme; 2014. 600 p. (Physiofachbuch).
616 ISBN: 3131392320.
- 617 64. O'Sullivan P. Diagnosis and classification of chronic low back pain disorders: maladaptive
618 movement and motor control impairments as underlying mechanism. *Man Ther*
619 2005;10(4):242. eng. doi:10.1016/j.math.2005.07.001.
- 620 65. Hill JC, Whitehurst DGT, Lewis M, Bryan S, Dunn KM, Foster NE, Konstantinou K, Main CJ,
621 Mason E, Somerville S, Sowden G, Vohora K, Hay EM. Comparison of stratified primary
622 care management for low back pain with current best practice (STarT Back): a
623 randomised controlled trial. *The Lancet* 2011;378(9802):1560. doi:10.1016/S0140-
624 6736(11)60937-9.
- 625 66. Fersum KV, Dankaerts W, O'Sullivan PB, Maes J, Skouen JS, Bjordal JM, Kvåle A.
626 Integration of subclassification strategies in randomised controlled clinical trials
627 evaluating manual therapy treatment and exercise therapy for non-specific chronic low
628 back pain: a systematic review. *Br J Sports Med* 2010;44(14):1054. eng.
629 doi:10.1136/bjism.2009.063289.
- 630 67. Foster NE, Mullis R, Hill JC, Lewis M, Whitehurst, David G T, Doyle C, Konstantinou K,
631 Main C, Somerville S, Sowden G, Wathall S, Young J, Hay EM. Effect of stratified care for
632 low back pain in family practice (IMPACT Back): a prospective population-based
633 sequential comparison. *Ann Fam Med* 2014;12(2):102. eng. doi:10.1370/afm.1625.
- 634 68. Slater SL, Ford JJ, Richards MC, Taylor NF, Surkitt LD, Hahne AJ. The effectiveness of sub-
635 group specific manual therapy for low back pain: a systematic review. *Man Ther*
636 2012;17(3):201. eng. doi:10.1016/j.math.2012.01.006.
- 637 69. Depner M, Fuchs O, Genuneit J, Karvonen AM, Hyvarinen A, Kaulek V, Roduit C, Weber J,
638 Schaub B, Lauener R, Kabesch M, Pfefferle PI, Frey U, Pekkanen J, Dalphin J-C, Riedler J,
639 Braun-Fahrlander C, Mutius E v., Ege MJ. Clinical and epidemiologic phenotypes of
640 childhood asthma. *Am J Respir Crit Care Med* 2014;189(2):129. eng.
641 doi:10.1164/rccm.201307-1198OC.
- 642

643

644

645 Table S1 online: Functional measurements of TMJ region and cervical spine

646 Variables were used for identifying clinical patterns among TMD patients by explorative data analysis

Measurements	Description
<i>Conti Questionnaire</i>	Contains 10 questions that are related to problems originating from the temporomandibular region. Each question has three ranking options (0=none: 1=present: and 3=strong or bilateral). The likelihood of a CMD is divided into 4 subgroups: 4- 9, none: 9-14, minimal: 15-21, moderate: 21-23, strong
<i>Colored Analogue Scale (CAS)</i>	Pain intensity scale similar to the visual analogue scale transformed in an increasing colored line in mm that represents the pain intensity
<i>Range of motion of TMJ</i>	Using a ruler of 15 cm, starting at 0, the active ROM of TMJ is measured including mouth opening, lateral shift, backward and forward movement of the jaw
<i>Mechanosensitivity of cervical and masticatory muscles</i>	The mechanical pressure pain threshold is assessed of the masticatory system and the neck muscles by a digital in kilogram force (Kgf). Muscles measured: Masseter, Temporalis, Upper Trapezius and Obliquus Capitis Inferior
<i>Neck Disability Index (NDI)</i>	A dimension-specific index that reflects "functional limitation" in neck disorders (includes 10 items (activities) with six different response options, ranging from "no disability" (0) to "complete disability."(5) The total score is 50. A higher score indicates more pain and disability
<i>Cervical Range of Motion (CROM)</i>	Measurement of cervical spine flexion, extension, rotation and lateral flexion using an inclinometer

<i>Cranial cervical Flexion Test (CCFT)</i>	Measures the cervical flexor muscle synergy during upper cervical flexion. A pressure sensor positioned under the neck enables targeted increases in upper cervical flexion ROM by raising pressure in the sensor at 2 mm Hg increments from a baseline of 20, rising to 30mm Hg.
<i>Flexion Rotation Test (FRT)</i>	Passive rotation of the cervical spine in maximal flexion measured in supine. Subjective pain response and range of rotation is recorded.
<i>N° of cervical signs</i>	Palpation of the three upper cervical spine motion segments was to assess segmental mobility and pain. Score is sum of number of symptomatic findings.

647

648 Table 1: baseline characteristic of the study participants according to subgroups

	Healthy (n=21)	Just signs (n=23)	Arthrogen (n=18)	Myogen (n=19)	Mixed (n=63)	p-Value
Female sex: n (%)	11 (52%)	18(78%)	15 (84%)	15 (89%)	54 (83%)	0.045
Age in years: mean (SD)	33.15 (9.86)	32.61 (7.91)	35.11 (9.58)	31.11(8.55)	36 (13.61)	0.44
CONTI: mean (SD)	1.619 (1.15)	1.91 (0.99)	6.50 (2.55)	7.23 (3.33)	8.57 (3.59)	<0.0001
Mouth opening in mm: mean (SD)	46.95 (5.47)	42.34 (4.45)	42.61 (6.91)	46.52 (5.11)	42.30 (6.65)	0.005

649

650

651 Table 2: Factor loadings of measured variables

652 The table shows contribution of each measured variable to each identified dimension by means of
 653 correlation coefficients. Grey shaded cells indicate high contribution. Based on correlation coefficients
 654 clinical characterization of dimensions is carried out.

variables	Factor 1 "mechano- sensitivity"	Factor 2 "cervical ROM"	Factor 3 "Cervical/mastic at. dysfunction and pain"	Factor 4 "jaw movement"	Factor 5 "ROM and endurance upp. cervical spine"
MS trap right	0.88	-0.13	-0.15	0.12	-0.02
MS trap left	0.83	-0.13	-0.28	0.03	-0.10
MS obliq right	0.86	-0.08	-0.16	0.04	0.09
MS obliq left	0.89	-0.04	-0.17	0.11	0.06
MS temp right	0.85	0.02	-0.01	-0.03	-0.10
MS temp left	0.85	0.06	-0.01	-0.03	0.02
MS mass right	0.82	0.16	0.00	0.00	0.09
MS mass left	0.80	0.12	0.06	0.07	0.10
Nr° of cervical signs	-0.64	-0.25	0.33	-0.14	-0.37
Flexion	-0.14	0.54	-0.05	0.18	0.04
Extension	0.10	0.72	-0.13	0.11	0.05
Lateralflex right	0.12	0.77	-0.08	0.00	0.11
Lateralflex left	0.08	0.80	-0.05	-0.10	0.08
Rotation right	-0.06	0.67	-0.13	0.13	0.05
Rotation left	-0.04	0.81	-0.08	0.13	0.10
pain acute	0.07	-0.13	0.47	0.11	0.11

NDI	-0.21	-0.28	0.62	-0.10	0.16
CONTI	-0.28	-0.16	0.57	-0.24	0.21
pain FRT right	-0.18	0.02	0.72	-0.01	-0.42
pain FRT left	-0.25	-0.08	0.67	-0.10	-0.29
mouth opening	0.20	0.22	0.17	0.43	-0.06
lateral shift left	-0.04	-0.03	0.03	0.70	-0.01
lateral shift right	-0.09	0.10	-0.25	0.69	0.04
Forward movement	0.08	0.16	-0.02	0.67	-0.02
Backward movement	0.11	0.03	-0.06	0.45	0.11
FRT ROM left	0.09	0.29	0.04	0.03	0.67
FRT ROM right	0.01	0.02	-0.11	-0.05	0.78
CCFT endurance	-0.01	0.11	0.24	0.30	0.45

655

656

657 Table 3: clinical pattern of subgroups is shown with respect to the cervical and masticatory systems.

658 Legend table 3: Arrows indicate effects according to effect sizes. One arrow is a small effect, two arrows


659 a medium effect and three arrows a large effect.

	mechanosensitivity	Cervical ROM	Cervical and masticatory dysfunction	Jaw movement	Upper cervical ROM/endurance
--	--------------------	--------------	--------------------------------------	--------------	------------------------------


Mixed	↓↓↓	↓↓	↓↓↓	↓↓	-
Myogen	↓	↓	↓↓↓	↓↓	-
Arthogen	-	-	↓↓↓	↓↓	-
Just signs	-	-	-	↓↓	-

660

661



663 Title figure 2: Scores of all individuals on each of the five extracted factors representing clinical
 664 dimensions
 665 Legend figure 2: Black Cs represent the control group including the control group with symptoms of
 666 TMD (“Just signs”). Grey Ts represent the TMD group including the “Arthrogen”, “Myogen” and “Mixed”
 667 subgroup. Each plot shows scores of two dimension. E.g. the very left top plot depicts scores of
 668 dimension 1 on x-axis and scores of dimension 2 on y-axis Separation of dots with respect to group
 669 membership indicate distinct patterns.



670

671 Title figure 3: Standardized mean differences of clinical dimensions between subgroups of TMD

672 Legend figure 3: Differences ($\pm 95\%$ Confidence Intervals) are shown between each of the subgroups to

673 control group with respect to all clinical dimensions calculated by linear regression analysis. Factors

674 representing a summary variable of each clinical dimension and single variables contributing to

675 respective dimension are depicted. Results are to be interpreted as effect sizes (beta). Model is adjusted

676 for age and gender where necessary.

